Luteolin has been reported to inhibit or reverse EMT in several cancers through regulating a variety of signaling pathways, such as Notch signaling in gastric cancer [259], HIF-1α/VEGF and β3 integrin/FAK signaling pathways in melanoma [260], and PI3K/AKT-NF-κB-Snail pathway in lung cancer [261], making luteolin an interesting therapeutic candidates as complementary medicine for a wide range of cancers [262]. This evidence concerns the gene AKT1 and lung carcinoma.